Giuseppe Di Lorenzo

Salerno, 84134, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 316 publications

Trastuzumab Deruxtecan in Metastatic Urothelial Carcinoma with NGS-Detected ERBB2 Amplification: A Four-Patient Real-World Case Series.

Trastuzumab Deruxtecan in Metastatic Urothelial Carcinoma with NGS-Detected ERBB2 Amplification: A Four-Patient Real-World Case Series.

Journal: Current oncology (Toronto, Ont.)
Published: June 16, 2026

Evolving Therapeutic Landscape in Non-Muscle-Invasive Bladder Cancer (NMIBC).

Evolving Therapeutic Landscape in Non-Muscle-Invasive Bladder Cancer (NMIBC).

Journal: Oncology
Published: June 15, 2026

PROTEUS: A Practice-changing Trial, but Are We Ready to Embrace Perioperative Apalutamide for All High-risk Patients?

PROTEUS: A Practice-changing Trial, but Are We Ready to Embrace Perioperative Apalutamide for All High-risk Patients?

Journal: European urology oncology
Published: June 07, 2026

PEACE: Development and Validation of a Brief Five-Item Sleep Quality Scale for Community and Primary Care.

PEACE: Development and Validation of a Brief Five-Item Sleep Quality Scale for Community and Primary Care.

Journal: Medicina (Kaunas, Lithuania)
Published: March 13, 2026

Real-world outcomes of second-line pembrolizumab in urothelial carcinoma: a multicenter analysis from the Campania Oncological Network (ROC).

Real-world outcomes of second-line pembrolizumab in urothelial carcinoma: a multicenter analysis from the Campania Oncological Network (ROC).

Journal: BMC cancer
Published: January 20, 2026

BLOSSOM Dietary Habits and 1-Year Intravesical Recurrence in High-Risk Non-Muscle-Invasive Bladder Cancer Treated with BCG.

BLOSSOM Dietary Habits and 1-Year Intravesical Recurrence in High-Risk Non-Muscle-Invasive Bladder Cancer Treated with BCG.

Journal: Current oncology (Toronto, Ont.)
Published: January 15, 2026

Neoadjuvant Therapy in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer: Recent Progress, Challenges, and Future Directions in the Era of TAR-200 and Enfortumab Vedotin Plus Pembrolizumab.

Neoadjuvant Therapy in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer: Recent Progress, Challenges, and Future Directions in the Era of TAR-200 and Enfortumab Vedotin Plus Pembrolizumab.

Journal: Oncology and therapy
Published: December 22, 2025

Re: Andrea Necchi, Félix Guerrero-Ramos, Paul L. Crispen, et al. Gemcitabine Intravesical System plus Cetrelimab or Cetrelimab Alone as Neoadjuvant Therapy in Patients with MIBC: Primary Analysis and Biomarker Results of SunRISe-4. J Clin Oncol. In press. https://doi.org/10.1200/JCO-25-02382.

Re: Andrea Necchi, Félix Guerrero-Ramos, Paul L. Crispen, et al. Gemcitabine Intravesical System plus Cetrelimab or Cetrelimab Alone as Neoadjuvant Therapy in Patients with MIBC: Primary Analysis and Biomarker Results of SunRISe-4. J Clin Oncol. In press. https://doi.org/10.1200/JCO-25-02382.

Journal: European urology oncology
Published: December 15, 2025

Serum copper, rubidium, selenium, strontium, and zinc and psychophysical health in adults of the Sarno river Basin: PREVES-STOP 2025 community biomonitoring results.

Serum copper, rubidium, selenium, strontium, and zinc and psychophysical health in adults of the Sarno river Basin: PREVES-STOP 2025 community biomonitoring results.

Journal: Journal of basic and clinical physiology and pharmacology
Published: November 10, 2025

The Role of Homologous Recombination Deficiency (HRD) in Renal Cell Carcinoma (RCC): Biology, Biomarkers, and Therapeutic Opportunities.

The Role of Homologous Recombination Deficiency (HRD) in Renal Cell Carcinoma (RCC): Biology, Biomarkers, and Therapeutic Opportunities.

Journal: Current oncology (Toronto, Ont.)
Published: October 25, 2025

Re: Gerhardt Attard, Neeraj Agarwal, Julie Graff, et al. Niraparib plus Abiraterone Acetate and Prednisone for HRR-mutated Metastatic Castration-sensitive Prostate Cancer: Results from the AMPLITUDE Phase 3 Trial. J Clin Oncol 2025;43(17 Suppl):LBA5006.

Re: Gerhardt Attard, Neeraj Agarwal, Julie Graff, et al. Niraparib plus Abiraterone Acetate and Prednisone for HRR-mutated Metastatic Castration-sensitive Prostate Cancer: Results from the AMPLITUDE Phase 3 Trial. J Clin Oncol 2025;43(17 Suppl):LBA5006.

Journal: European urology oncology
Published: June 09, 2025

Development and Validation of the PREVES-HOR Questionnaire: A Patient-Reported Measure of Hormone Therapy-Related Quality of Life in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy.

Development and Validation of the PREVES-HOR Questionnaire: A Patient-Reported Measure of Hormone Therapy-Related Quality of Life in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy.

Journal: Oncology
Published: May 30, 2025
Showing 1-12 of 316

Last Updated: 09/26/2026